Loading…
The relationship between sleep and immune function is bidirectional, deeply integrated, and clinically underappreciated. Sleep is not a passive state of rest but an active, highly regulated biological process during which the immune system undergoes critical maintenance, recalibration, and memory consolidation — tasks that cannot be adequately performed during wakefulness.
The landmark study by Cohen et al. (2009) in the Archives of Internal Medicine directly quantified this relationship: adults sleeping fewer than 7 hours per night were approximately 3 times more likely to develop a common cold after experimental rhinovirus inoculation compared to those sleeping 8 or more hours, with the risk rising to 4 times for those sleeping under 6 hours. This was a controlled experimental study, not observational inference — participants were quarantined after inoculation, eliminating exposure confounding.
The mechanisms through which sleep supports immune defence are multiple and interacting: cytokine production and regulation, natural killer (NK) cell activity, T-cell activation and memory, antibody production, and regulation of systemic inflammation. Disrupting sleep impairs all of these pathways simultaneously — sleep is not merely adjunctive to immune function; it is integral to it.
Cytokines are small signalling proteins produced by immune cells that regulate the intensity and character of the immune response. Several key cytokines — including interleukin-1β (IL-1β), tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-12 (IL-12) — are produced at elevated levels during sleep and are directly somnogenic (promoting sleep themselves), creating an integrated feedback loop.
Slow-wave sleep (SWS) — the deepest stage of non-REM sleep — is particularly associated with elevated growth hormone (GH) secretion and peak production of pro-inflammatory cytokines, which coordinate repair processes and immune memory consolidation. Cortisol, which has immunosuppressive effects, reaches its nadir during the first half of the night when SWS predominates, allowing unimpeded immune activation during this window.
Pro-inflammatory cytokines produced during sleep serve a double role: they support immune defence while simultaneously feeding back to the brain to prolong and deepen sleep — particularly in response to infection. This explains why people feel sleepier when ill. The fever, fatigue, and somnolence of acute infection are adaptive responses — not mere symptoms — that optimise the immune response by increasing sleep depth and duration.
Chronic sleep restriction disrupts this cytokine rhythm, producing a state of low-grade systemic inflammation — elevated basal IL-6, TNF-α, and CRP — without the corresponding infection-protective peaks. This pattern is associated with increased cardiovascular disease, type 2 diabetes, and impaired vaccine response independent of other lifestyle factors.
Natural killer (NK) cells are innate immune lymphocytes that provide first-line defence against viral infections and tumour cells without requiring prior antigen sensitisation — a critical advantage during novel pathogen exposure. Their activity is highly sensitive to sleep duration and quality.
Irwin et al. (1996) demonstrated that a single night of partial sleep deprivation (reducing sleep from a normal duration to 3–4 hours) reduced NK cell cytotoxicity by approximately 28% in healthy adults. This suppression was observable the following morning — after just one night of inadequate sleep — and recovered with the next night of normal sleep.
Longitudinal studies in shift workers — a population chronically subject to circadian disruption and sleep curtailment — show significantly elevated rates of certain cancers (particularly breast cancer in night-shift nurses), which has been partly attributed to sustained NK cell suppression alongside other mechanisms of immune dysregulation. The International Agency for Research on Cancer (IARC) classifies night shift work as a probable carcinogen (Group 2A).
Vaccine immunogenicity is impaired by sleep deprivation around the time of vaccination. Studies of hepatitis B and influenza vaccination have demonstrated that subjects sleeping fewer than 6 hours in the nights surrounding vaccination mount significantly lower antibody titres — sometimes below the threshold considered protective — compared to adequately rested controls. This has direct clinical relevance for vaccination scheduling guidance.
Beyond the landmark rhinovirus study, epidemiological evidence consistently links short sleep duration with elevated infection risk across a range of pathogens. Prather et al. (2015) replicated and extended these findings, confirming the dose-response relationship: each additional hour of sleep below the recommended 7–9 hours was associated with progressively higher infection risk.
COVID-19 outcomes add a contemporary dimension to this evidence. Multiple observational studies during the pandemic found that healthcare workers with shorter pre-infection sleep duration and higher rates of insomnia had worse COVID-19 clinical outcomes, including higher hospitalisation rates — consistent with pre-existing evidence of sleep's role in antiviral defence.
The immune effects of sleep deprivation extend to adaptive immunity — the arm of the immune system responsible for long-term pathogen memory. T helper cell function, B-cell antibody class switching, and immunological memory consolidation all preferentially occur during sleep. Chronic short sleepers therefore not only have impaired initial responses to pathogens but also weaker and shorter-lived immune memory.
Clinicians should consider sleep as a modifiable immune risk factor — as clinically relevant as smoking, diet, and physical activity. Routine enquiry about sleep quality and duration in patients with recurrent infections, poor vaccine responses, or other immune-related presentations is warranted.
Cognitive Behavioural Therapy for Insomnia (CBT-I) is the first-line treatment for chronic insomnia according to the American College of Physicians, the British Association for Psychopharmacology, and most major sleep medicine societies. It outperforms sleep medication in both short-term efficacy and durability of improvement. Clinicians can deliver brief CBT-I components (sleep restriction, stimulus control, cognitive restructuring) in primary care settings or refer to digital CBT-I programmes.
The sleep hygiene principles with the strongest evidence base are stimulus control (keeping the bed exclusively for sleep and sex), sleep restriction (initially limiting time in bed to actual sleep time to consolidate sleep efficiency), consistent wake times (anchoring the circadian clock), and pre-sleep wind-down routines (reducing sympathetic nervous system arousal before bed).
Screen use before bed deserves clinical attention in both children and adults. Blue-spectrum light from screens suppresses melatonin secretion via retinal melanopsin receptors, delaying circadian phase and increasing sleep-onset latency. A pre-bed screen abstinence of 60 minutes is the most commonly recommended minimum; 'night mode' settings reduce but do not eliminate the melatonin-suppressing effect.
Alcohol is frequently misused as a sleep aid — it reduces sleep-onset latency but substantially disrupts sleep architecture, reducing REM sleep and increasing nocturnal awakenings in the second half of the night. Clinicians should explicitly counsel patients that alcohol worsens sleep quality despite its sedative initial effect, and that its role as a 'sleep aid' is a harmful myth reinforced by the sedating experience of sleep onset.
Prescription hypnotics (benzodiazepines, Z-drugs) are appropriate only for short-term management of insomnia in specific clinical contexts. They should not be prescribed as first-line treatment for chronic insomnia, given the evidence base favouring CBT-I and the significant risks of tolerance, dependence, and residual cognitive impairment — particularly in older adults, where sedating hypnotics are associated with increased fall and fracture risk.
Summary of evidence-based relationships between sleep duration and specific immune parameters. All findings are from peer-reviewed controlled studies in healthy adults unless otherwise noted.
| Sleep Duration | Relative Infection Risk | NK Cell Activity | Vaccine Antibody Response |
|---|---|---|---|
| ≥ 8 hours hours/night | Lowest (reference) | Optimal | Highest titres |
| 7–8 hours hours/night | Baseline low risk | Near-optimal | Adequate (above protective threshold) |
| 6–7 hours hours/night | ~1.5–2× increased | Mildly reduced | Reduced but likely adequate |
| < 6 hours hours/night | ~4× increased (rhinovirus) | ~28% reduction after 1 night | Significantly reduced; may fall below protective threshold |
| < 5 hours hours/night | Highest risk group | Substantially impaired | Least protective; may require booster |